The use of bivalent vaccine in preventing infection in cervical carcinogenesis Human Papilloma Virus (HPV)

Celso Dias Batista

The use of bivalent vaccine in preventing infection in cervical carcinogenesis Human Papilloma Virus (HPV)

Celso Dias Batista

Faculdade Unica de Ipatinga, Brazil

: J Pharm Drug Deliv

Abstract

Background: The HPV vaccines have shown promise in protecting against infection and the development of related injuries to some types of HPV (LEPIQUE; RABACHINI and VILLA, 2009). Goals: To present the bivalent vaccine against high-risk HPV (16 and 18) as a way to prevent cervical cancer. Methodology: Literature review, documental, retrospective based on national and international journals indexed and Qualis A. Development: It was in this work specifically the bivalent vaccine was used because of the fact that a vaccine that only protects against the types of high oncogenic risk. The bivalent vaccine containing 20 micrograms like particle HPV L1, 16 and 20 micrograms of virus-like particle HPV 18 L1 at each dose associated with AS04 adjuvant containing 500 micrograms of aluminum hydroxide and 5 micrograms of monophosphoryl lipid- 3-deacylated. Clinical studies in humans have demonstrated that the HPV 16/18 VLP AS04 adjuvant with an initial induce significantly higher antibody response than that obtained with aluminum hydroxide as adjuvant alone, and that it stays response for at least 4 years (HARPER , 2008). Conclusion: The vaccine has proven to be most effective when administered before onset of sexual activity and vaccination campaigns should target the tweens and teens. It is expected that the increase in the use of vaccine to be a prophylactic strategy to reach 70% or more of the cases of cervical carcinogenesis.